Craig Hallum slashes price target on Ironwood Pharmaceuticals Inc [IRWD] – find out why.

Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] stock went on an upward path that rose over 0.29% on Tuesday, amounting to a one-week price increase of more than 2.37%. The company report on January 8, 2024 at 7:00 PM that Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation.

– Newly published data highlights additional efficacy endpoints from trial –.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

– Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years with functional constipation –.

Over the last 12 months, IRWD stock rose by 20.10%. The one-year Ironwood Pharmaceuticals Inc stock forecast points to a potential upside of 25.41. The average equity rating for IRWD stock is currently 1.43, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $2.15 billion, with 154.03 million shares outstanding and 152.03 million shares in the current float. Compared to the average trading volume of 2.56M shares, IRWD stock reached a trading volume of 3898721 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Ironwood Pharmaceuticals Inc [IRWD]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IRWD shares is $18.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IRWD stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Craig Hallum have made an estimate for Ironwood Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 17, 2024.

The Average True Range (ATR) for Ironwood Pharmaceuticals Inc is set at 0.44, with the Price to Sales ratio for IRWD stock in the period of the last 12 months amounting to 4.98. Price to Free Cash Flow for IRWD in the course of the last twelve months was 9.50 with Quick ratio for the last quarter at 0.90.

IRWD Stock Performance Analysis:

Ironwood Pharmaceuticals Inc [IRWD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.37. With this latest performance, IRWD shares gained by 20.31% in over the last four-week period, additionally plugging by 24.44% over the last 6 months – not to mention a rise of 20.10% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IRWD stock in for the last two-week period is set at 70.88, with the RSI for the last a single of trading hit 72.67, and the three-weeks RSI is set at 69.33 for Ironwood Pharmaceuticals Inc [IRWD]. The present Moving Average for the last 50 days of trading for this stock 11.38, while it was recorded at 13.56 for the last single week of trading, and 10.38 for the last 200 days.

Insight into Ironwood Pharmaceuticals Inc Fundamentals:

Ironwood Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 0.90.


With the latest financial reports released by the company, Ironwood Pharmaceuticals Inc posted 0.27/share EPS, while the average EPS was predicted by analysts to be reported at 0.27/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IRWD.

Ironwood Pharmaceuticals Inc [IRWD] Institutonal Ownership Details

The top three institutional holders of IRWD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in IRWD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in IRWD stock with ownership which is approximately 5.8325%.